COMT inhibitor

From Wikipedia, the free encyclopedia
Jump to: navigation, search

A COMT inhibitor is a drug that inhibits the action of catechol-O-methyl transferase. This enzyme is involved in degrading neurotransmitters. COMT inhibitors are used in the treatment of Parkinson's disease.

Pharmaceutical examples include entacapone,[1] tolcapone,[2] and nitecapone. Entacapone is only peripherally active, whereas both tolcapone and nitecapone are active in both the periphery and central nervous system. Tolcapone and nitecapone are known to be hepatotoxic, whereas entacapone is not.[citation needed]

References[edit]

  1. ^ Nissinen E, Nissinen H, Larjonmaa H et al. (September 2005). "The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats". J Neural Transm 112 (9): 1213–1221. doi:10.1007/s00702-004-0262-4. PMID 15614425. 
  2. ^ Giakoumaki SG, Roussos P, Bitsios P (June 2008). "Improvement of Prepulse Inhibition and Executive Function by the COMT Inhibitor Tolcapone Depends on COMT Val158Met Polymorphism". Neuropsychopharmacology 33 (13): 3058–3068. doi:10.1038/npp.2008.82. PMID 18536698.